Baidu
map

Eur Ann Allergy Clin Immunol:移动应用apps在过敏性呼吸道疾病中的作用

2018-10-31 AlexYang MedSci原创

最近,有研究人员对移动应用在过敏性呼吸道疾病中的作用进行了多中心的调查。他们研究的主要目的是调查在过敏性呼吸道疾病的控制和治疗过程中,移动应用apps的使用和效果情况。研究人员利用包括12个多选问题的调查问卷进行研究,并包括了360名参与者(153名男性和207名女性)。值得注意的是,290名参与者拥有移动手机。120名为个人电脑,68名为平板电脑。123名报道经常使用移动应用apps,209名为

最近,有研究人员对移动应用在过敏性呼吸道疾病中的作用进行了多中心的调查。他们研究的主要目的是调查在过敏性呼吸道疾病的控制和治疗过程中,移动应用apps的使用和效果情况。

研究人员利用包括12个多选问题的调查问卷进行研究,并包括了360名参与者(153名男性和207名女性)。值得注意的是,290名参与者拥有移动手机。120名为个人电脑,68名为平板电脑。123名报道经常使用移动应用apps,209名为偶尔使用者,76名从来不使用也不下载app。的确,259名参与者从来不使用医疗或者护理app,只有8名受试者报道经常使用上述工具性apps。当问及是否受试者会下载与他们医疗状况直接相关的app(过敏、小船和鼻炎)时,87.2%的参与者的答案是否定的。另外,在那些自我报道使用与过敏/哮喘相关apps的患者中,只有2名报道经常使用并且持续到数月。大多数的参与者相信apps能够提供相关的支持,但是只有25/360参与者发现那些apps是"真正有用"的,而44名参与者认为是有帮助的但是非必需。

最后,研究人员指出,他们的数据表明了医疗领域里面的apps,尤其是过敏性呼吸道方面的apps是受患者欢迎的,但是他们对apps的使用随着时间的推移而逐步减少。因此,在未来应该关注apps的质量,并且apps的设计对患者具有更强的针对性。另外,健康专家对apps的作用也应该充分的利用。

原始出处:

Lombardi C, Bonini M, Passalacqua G et al. The role of mobile apps in allergic respiratory diseases: an Italian multicentre survey report. Eur Ann Allergy Clin Immunol. 15 Oct 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951784, encodeId=bc5c1951e84fa, content=<a href='/topic/show?id=dc43e51647a' target=_blank style='color:#2F92EE;'>#移动应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75164, encryptionId=dc43e51647a, topicName=移动应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 25 02:54:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047036, encodeId=9d66204e03620, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 23 17:54:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977253, encodeId=a6ef19e72536d, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Jan 30 01:54:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282472, encodeId=ec4512824e262, content=<a href='/topic/show?id=700239e0772' target=_blank style='color:#2F92EE;'>#呼吸道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39707, encryptionId=700239e0772, topicName=呼吸道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329166, encodeId=e3581329166bf, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951784, encodeId=bc5c1951e84fa, content=<a href='/topic/show?id=dc43e51647a' target=_blank style='color:#2F92EE;'>#移动应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75164, encryptionId=dc43e51647a, topicName=移动应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 25 02:54:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047036, encodeId=9d66204e03620, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 23 17:54:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977253, encodeId=a6ef19e72536d, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Jan 30 01:54:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282472, encodeId=ec4512824e262, content=<a href='/topic/show?id=700239e0772' target=_blank style='color:#2F92EE;'>#呼吸道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39707, encryptionId=700239e0772, topicName=呼吸道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329166, encodeId=e3581329166bf, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951784, encodeId=bc5c1951e84fa, content=<a href='/topic/show?id=dc43e51647a' target=_blank style='color:#2F92EE;'>#移动应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75164, encryptionId=dc43e51647a, topicName=移动应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 25 02:54:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047036, encodeId=9d66204e03620, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 23 17:54:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977253, encodeId=a6ef19e72536d, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Jan 30 01:54:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282472, encodeId=ec4512824e262, content=<a href='/topic/show?id=700239e0772' target=_blank style='color:#2F92EE;'>#呼吸道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39707, encryptionId=700239e0772, topicName=呼吸道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329166, encodeId=e3581329166bf, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2019-01-30 yyj062
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951784, encodeId=bc5c1951e84fa, content=<a href='/topic/show?id=dc43e51647a' target=_blank style='color:#2F92EE;'>#移动应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75164, encryptionId=dc43e51647a, topicName=移动应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 25 02:54:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047036, encodeId=9d66204e03620, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 23 17:54:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977253, encodeId=a6ef19e72536d, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Jan 30 01:54:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282472, encodeId=ec4512824e262, content=<a href='/topic/show?id=700239e0772' target=_blank style='color:#2F92EE;'>#呼吸道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39707, encryptionId=700239e0772, topicName=呼吸道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329166, encodeId=e3581329166bf, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2018-11-02 zhmscau
  5. [GetPortalCommentsPageByObjectIdResponse(id=1951784, encodeId=bc5c1951e84fa, content=<a href='/topic/show?id=dc43e51647a' target=_blank style='color:#2F92EE;'>#移动应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75164, encryptionId=dc43e51647a, topicName=移动应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Aug 25 02:54:00 CST 2019, time=2019-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047036, encodeId=9d66204e03620, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 23 17:54:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977253, encodeId=a6ef19e72536d, content=<a href='/topic/show?id=f37214590b2' target=_blank style='color:#2F92EE;'>#PPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14590, encryptionId=f37214590b2, topicName=PPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Jan 30 01:54:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282472, encodeId=ec4512824e262, content=<a href='/topic/show?id=700239e0772' target=_blank style='color:#2F92EE;'>#呼吸道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39707, encryptionId=700239e0772, topicName=呼吸道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329166, encodeId=e3581329166bf, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Nov 02 03:54:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2018-11-02 膀胱癌

相关资讯

Allergy Asthma Immunol Res:屋尘螨敏感的老年人鼻炎患者中,舌下免疫治疗的效果和安全性评估

最近,有研究人员确定了屋尘螨(HDM)舌下免疫治疗(SLIT)在患有AR的老年人患者中治疗的效果和安全性。研究包括了45名年龄不小于60岁的HDM诱导的AR患者,并分为2个小组,分别为SLIT治疗组(n=30)和对照组(n=15)。研究发现,在人口统计特征,鼻黏膜总症状得分(STSS),皮肤对HDMs的反应或者对HDMs的血清总的/特异的lgE水平在2个小组之间均没有显著额差异。在第1年,2个小组

秋季鼻炎 痛苦如“绝症”! 70岁呼吸科老主任教你一招破解

有一种疾病,我国不同程度的患病人群高达3亿人,相当于每4个人就有一个人在饱受折磨。那就是鼻炎。

盘点:鼻炎与治疗

【1】Expert Opin Pharmacother:苯磺酸贝托司汀在永久过敏性鼻炎中的治疗结果分析影响研究苯磺酸贝托司汀(BB)是二代H1抗组胺药物,作为一种滴眼液,在美国是通过FDA批准的可以用于过敏性结膜炎治疗的药物。在其他的国家,口服BB是广泛存在的,主要是用于过敏性鼻炎(AR)以及荨麻疹和慢性瘙痒症状的改善,并且与其他药物治疗的结果类似。最近,有研究人员对文献进行了综合的搜索,这些

盘点:鼻炎研究进展

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】J Agromedicine:美国农场经营者农药的使用、过敏性鼻炎和哮喘情况分析 最近,有研究人员在美国农场经营者中调查了特殊农药的使用与过敏性鼻炎以及哮喘

Cell Mol Biol (Noisy-le-grand):中国过敏性鼻炎儿童IL-31, IL-33和ST2血清水平调查

最近,有研究人员比较了儿童过敏性鼻炎(AR)和过敏性哮喘患者中IL-31, IL-33和ST2血清水平,并尝试阐释AR的发病机制。研究包括了36名患有间歇性AR的儿童患者,调查的时间为2013年1月到2016年12月。研究人员设置了2个对照组,过敏性哮喘组和健康对照组,并对所有参与者的过敏状态通过皮刺测试(SPT)进行了测试和确定,还利用ELISA对IL-31, IL-33和ST2血清水平进行了确

Ann Agric Environ Med:哮喘、鼻炎和湿疹与对乙酰氨基酚使用的相关性分析

对乙酰氨基酚是一种常见的儿童使用药物,越来越多的流行病学研究表明对乙酰氨基酚的使用可能是哮喘、过敏性鼻炎和特应性湿疹的风险因子。最近,有研究人员确定和鉴定了对乙酰氨基酚的使用与哮喘、过敏性鼻炎和特应性湿疹症状之间的相关性。研究包括了6-7岁的儿童(n=4510)、13-14岁的青少年(n=4721)和20-44岁的成年人(n=9386),分别占比 24.2%, 25.4%和50.4%。研究发现,乙

Baidu
map
Baidu
map
Baidu
map